Neoadjuvant Chemohormonal Therapy for Patients With Very-high Risk Localized Prostate Cancer in Clinical Stages T2 and T3a
In Vivo · 2026
DOI: 10.21873/invivo.14264 ↗Kurz gefasst
Fachartikel in der Zeitschrift In Vivo, 2026. Verfasst von Daiki Kikuchi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Renal and Urologic Surgery, Asahikawa Medical University, Asahikawa, Japan. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Neoadjuvant Therapy. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Renal and Urologic Surgery, Asahikawa Medical University, Asahikawa, Japan.
- Department of Renal and Urologic Surgery, Asahikawa Medical University, Asahikawa, Japan nqf38647@nifty.com.
Zitieren
APA
Kikuchi, D., Numakura, K., Miyauchi, K., Abe, N., Ohtani, M., Kobayashi, S., & Wada, N. (2026). Neoadjuvant Chemohormonal Therapy for Patients With Very-high Risk Localized Prostate Cancer in Clinical Stages T2 and T3a. In Vivo. https://doi.org/10.21873/invivo.14264
Vancouver
Kikuchi D, Numakura K, Miyauchi K, Abe N, Ohtani M, Kobayashi S, et al. Neoadjuvant Chemohormonal Therapy for Patients With Very-high Risk Localized Prostate Cancer in Clinical Stages T2 and T3a. In Vivo. 2026. doi:10.21873/invivo.14264
BibTeX
@article{Kikuchi2026,
author = {Kikuchi, Daiki and Numakura, Kazuyuki and Miyauchi, Kotona and Abe, Noriyuki and Ohtani, Miyu and Kobayashi, Shin and Wada, Naoki},
title = {Neoadjuvant Chemohormonal Therapy for Patients With Very-high Risk Localized Prostate Cancer in Clinical Stages T2 and T3a},
journal = {In Vivo},
year = {2026},
doi = {10.21873/invivo.14264}
}
EUVIMED